The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive insulin therapy could reduce HbA1c levels and dramatically reduce the progression of the microvascular complications of diabetes, including nephropathy, neuropathy, and retinopathy, when compared to conventional insulin therapy [2]. This evidence concerns the gene INS and retinal disorder.